carmustine has been researched along with Hematologic Neoplasms in 20 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens." | 9.27 | Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018) |
| "Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens." | 5.27 | Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018) |
| " Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) on days 2 through 5 (total 6 g/m(2)), and etoposide 700 mg/m(2) per day on days 2 through 4 (total 2,100 mg/m(2))." | 3.81 | Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. ( Ford, PA; Grant, SJ; Keck, G; Mick, R, 2015) |
| " We evaluated the possibility of a pharmacokinetic (PK) drug-drug interaction between the antiemetic agents and high-dose cyclophosphamide, cisplatin and BCNU (CPA/cDDP/BCNU)." | 2.69 | Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ( Bearman, SI; Cagnoni, PJ; Day, TC; Jones, RB; Matthes, S; Shpall, EJ, 1999) |
| "Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids." | 2.69 | Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. ( Alessandrino, EP; Bernasconi, C; Bernasconi, P; Caldera, D; Colombo, A; Klersy, C; Malcovati, L; Martinelli, G; Nascimbene, C; Varettoni, M; Vitulo, P; Volpini, E, 2000) |
| " We conclude that FBM-A is an effective and safe conditioning regimen for adults up to age 69 with hematologic malignancies who have low-, intermediate-, or high-risk scores according to the DRI." | 1.39 | Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant ( Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Köksal, M | 1 |
| Kersting, L | 1 |
| Schoroth, F | 1 |
| Garbe, S | 1 |
| Koch, D | 1 |
| Scafa, D | 1 |
| Sarria, GR | 1 |
| Leitzen, C | 1 |
| Heine, A | 1 |
| Holderried, T | 1 |
| Brossart, P | 1 |
| Zoga, E | 1 |
| Attenberger, U | 1 |
| Schmeel, LC | 1 |
| Heng, MS | 1 |
| Barbon Gauro, J | 1 |
| Yaxley, A | 1 |
| Thomas, J | 1 |
| Clemmons, AB | 1 |
| Orr, J | 1 |
| Andrick, B | 1 |
| Gandhi, A | 1 |
| Sportes, C | 1 |
| DeRemer, D | 1 |
| Slack, JL | 1 |
| Dueck, AC | 1 |
| Fauble, VD | 1 |
| Sproat, LO | 1 |
| Reeder, CB | 1 |
| Noel, P | 1 |
| Khera, N | 1 |
| Betcher, JA | 1 |
| Klein, JL | 1 |
| Leis, JF | 1 |
| Adams, RH | 1 |
| Milone, G | 1 |
| Leotta, S | 1 |
| Cupri, A | 1 |
| Fauci, AL | 1 |
| Spina, P | 1 |
| Parisi, M | 1 |
| Berritta, D | 1 |
| Tripepi, G | 1 |
| Rancea, M | 1 |
| Will, A | 1 |
| Borchmann, P | 1 |
| Monsef, I | 1 |
| Engert, A | 1 |
| Skoetz, N | 1 |
| Cioch, M | 1 |
| Jawniak, D | 1 |
| Kotwica, K | 1 |
| Wach, M | 1 |
| Mańko, J | 1 |
| Gorący, A | 1 |
| Klimek, P | 1 |
| Mazurkiewicz, E | 1 |
| Jarosz, P | 1 |
| Hus, M | 1 |
| Ford, PA | 1 |
| Grant, SJ | 1 |
| Mick, R | 1 |
| Keck, G | 1 |
| Novak, J | 1 |
| Dobrovolny, J | 1 |
| Brozova, J | 1 |
| Novakova, L | 1 |
| Kozak, T | 1 |
| Tsirigotis, P | 1 |
| Triantafyllou, K | 1 |
| Girkas, K | 1 |
| Giannopoulou, V | 1 |
| Ioannidou, E | 1 |
| Chondropoulos, S | 1 |
| Kalli, T | 1 |
| Papaxoinis, G | 1 |
| Pappa, V | 1 |
| Papageorgiou, E | 1 |
| Economopoulos, T | 1 |
| Ladas, SD | 1 |
| Dervenoulas, J | 1 |
| Wachowiak, J | 1 |
| Sykora, KW | 1 |
| Cornish, J | 1 |
| Chybicka, A | 1 |
| Kowalczyk, JR | 1 |
| Gorczyńska, E | 1 |
| Choma, M | 1 |
| Grund, G | 1 |
| Peters, C | 1 |
| Marks, DI | 1 |
| Lush, R | 1 |
| Cavenagh, J | 1 |
| Milligan, DW | 1 |
| Schey, S | 1 |
| Parker, A | 1 |
| Clark, FJ | 1 |
| Hunt, L | 1 |
| Yin, J | 1 |
| Fuller, S | 1 |
| Vandenberghe, E | 1 |
| Marsh, J | 1 |
| Littlewood, T | 1 |
| Smith, GM | 1 |
| Culligan, D | 1 |
| Hunter, A | 1 |
| Chopra, R | 1 |
| Davies, A | 1 |
| Towlson, K | 1 |
| Williams, CD | 1 |
| Ergene, U | 1 |
| Cağirgan, S | 1 |
| Pehlivan, M | 1 |
| Yilmaz, M | 1 |
| Tombuloğlu, M | 1 |
| Marks, R | 1 |
| Potthoff, K | 1 |
| Hahn, J | 1 |
| Ihorst, G | 1 |
| Bertz, H | 1 |
| Spyridonidis, A | 1 |
| Holler, E | 1 |
| Finke, JM | 1 |
| Mahendra, P | 1 |
| Johnson, D | 1 |
| Scott, MA | 2 |
| Jestice, HK | 1 |
| Hood, IM | 1 |
| Ager, S | 1 |
| Bass, G | 2 |
| Barker, P | 1 |
| Boraks, PA | 1 |
| Bloxham, DM | 1 |
| Baglin, TP | 1 |
| Marcus, RE | 2 |
| Knudsen, LM | 1 |
| Gaarsdal, E | 1 |
| Jensen, L | 1 |
| Nielsen, KJ | 1 |
| Nikolaisen, K | 1 |
| Johnsen, HE | 1 |
| Gandhi, MK | 1 |
| Jestice, K | 1 |
| Bloxham, D | 1 |
| Cagnoni, PJ | 1 |
| Matthes, S | 1 |
| Day, TC | 1 |
| Bearman, SI | 1 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| Alessandrino, EP | 1 |
| Bernasconi, P | 1 |
| Colombo, A | 1 |
| Caldera, D | 1 |
| Martinelli, G | 1 |
| Vitulo, P | 1 |
| Malcovati, L | 1 |
| Nascimbene, C | 1 |
| Varettoni, M | 1 |
| Volpini, E | 1 |
| Klersy, C | 1 |
| Bernasconi, C | 1 |
| Steingrimsdottir, H | 1 |
| Gruber, A | 1 |
| Björkholm, M | 1 |
| Svensson, A | 1 |
| Hansson, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant[NCT04535141] | Phase 3 | 91 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Re[NCT02635984] | Phase 3 | 108 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation[NCT03821519] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-13 | Recruiting | ||
| A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796] | Phase 2 | 108 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The total number of rescue medications needed for breakthrough chemotherapy-induced nausea and vomiting were calculated, starting from the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for CINV prophylaxis." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).
| Intervention | number of rescue medication (Mean) |
|---|---|
| Usual Care | 0.47 |
| Olanzapine | 1.17 |
"The total number of rescue medications needed acute was calculated, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for chemotherapy-induced nausea and vomiting (CINV) prophylaxis." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)
| Intervention | number of rescue medication (Mean) |
|---|---|
| Usual Care | 0.08 |
| Olanzapin | 0.10 |
"Starting with the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions. Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely in the first 24 hours following receipt of chemotherapy." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration (Up to day 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 44 | 1 |
| Usual Care | 43 | 3 |
The frequency of somnolence was determined as the number of patients who experienced somnolence based on Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). The number of subjects has somnolence during the study period was counted. (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| subjects have somnolence | subjects do not have somnolence | |
| Olanzapine | 1 | 42 |
| Usual Care | 0 | 46 |
The number of emesis episodes in acute phase was defined as the number of subjects with no emesis, 1 emesis, and 2 or more emesis. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| No emesis episodes | 1 emesis episode | 2 or more emesis episodes | |
| Olanzapine | 36 | 6 | 3 |
| Usual Care | 32 | 9 | 5 |
: The number of subjects who did not experience emesis, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy. Met endpoint = 0 emesis. (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 45 | 0 |
| Usual Care | 45 | 1 |
"Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions, starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~The number of subjects who experienced never or rarely nausea were considered as met the endpoint while those who experienced occasionally, frequently or almost constantly were considered as not met the endpoint." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2-12).
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 27 | 18 |
| Usual Care | 19 | 27 |
"To determine the number of subjects achieving minimal nausea was defined as the frequency of participants responded to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea question In the last 24 hours, how often did you have nausea? as rarely or less Starting with the first dose of chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~PRO-CTCAE of nausea scale includes categories: Never, Rarely, Occasionally, Frequently, Almost constantly To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely and the score reported for the Pro-CTCAE question for nausea severity cannot exceed mild" (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Yes | No | |
| Olanzapine | 25 | 20 |
| Usual Care | 15 | 31 |
Prolongation of corrected QTc interval graded as defined in Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Corrected QTc was calculated using Fredericia's Formula. Corrected QT interval (QTc) = QT interval / (60/Heart rate)^0.33. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2- 12).
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | None | |
| Baseline Olanzapine | 4 | 0 | 0 | 0 | 0 | 41 |
| Baseline Usual Care | 3 | 0 | 0 | 0 | 0 | 43 |
| Olanzapine Post-chemo Day 1 | 3 | 0 | 0 | 0 | 0 | 42 |
| Olanzapine- End of Study | 3 | 0 | 1 | 0 | 0 | 41 |
| Usual Care End of Study | 3 | 0 | 1 | 0 | 0 | 42 |
| Usual Care Post-chemo Day 1 | 2 | 0 | 0 | 0 | 0 | 44 |
"The severity of nausea in the delayed phase was defined as the response of the subject to the PRO- CTCAE nausea question.~Starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy (PRO-CTCAE) Scale: Never, Rarely, Occasionally, Frequently, Almost constantly~o meet the endpoint, the subject could not have answered a score as higher than mild in the period of time starting 24 hours after the last dose of chemotherapy and continuing until the 5th day following receipt of chemotherapy ." (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 31 | 24 |
| Usual Care | 23 | 23 |
Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (< 25 mm on a 100 mm visual analog scale [VAS]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy. (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 13 |
| Triplet Therapy Plus Olanzapine | 28 |
Reported as acute [chemotherapy days]. All assessment with all VAS < 25 mm on days of chemotherapy (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 33 |
| Triplet Therapy Plus Olanzapine | 39 |
Reported for delayed [5 days after chemotherapy administration] All assessment with all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 16 |
| Triplet Therapy Plus Olanzapine | 34 |
(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases [chemotherapy days plus 5 days after] (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 6 |
| Triplet Therapy Plus Olanzapine | 13 |
Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in acute phase (days of chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 31 |
| Triplet Therapy Plus Olanzapine | 39 |
Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in delayed phase (5 days after chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 15 |
| Triplet Therapy Plus Olanzapine | 31 |
No nausea (all VAS <5 mm) in overall assessment period (days of chemotherapy plus five days after) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 6 |
| Triplet Therapy Plus Olanzapine | 18 |
Reported for overall phases [chemotherapy days plus 5 days after] where all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 14 |
| Triplet Therapy Plus Olanzapine | 30 |
1 review available for carmustine and Hematologic Neoplasms
| Article | Year |
|---|---|
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmust | 1996 |
6 trials available for carmustine and Hematologic Neoplasms
| Article | Year |
|---|---|
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busul | 2011 |
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplas | 2008 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmust | 1996 |
Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cisplatin; | 1999 |
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Prescho | 2000 |
14 other studies available for carmustine and Hematologic Neoplasms
| Article | Year |
|---|---|
Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy.
Topics: Bone Marrow; Carmustine; Etoposide; Hematologic Neoplasms; Humans; Radiation Injuries; Radiotherapy | 2023 |
Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial I | 2020 |
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carm | 2013 |
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytar | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2014 |
Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Topics: Adult; Biosimilar Pharmaceuticals; Carmustine; Female; Filgrastim; Granulocyte Colony-Stimulating Fa | 2014 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; C | 2015 |
Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carmustine; Cytarab | 2016 |
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capsule Endoscopy; Carmustine; Cytarabi | 2008 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2002 |
Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Com | 2007 |
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bloo | 1996 |
The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; | 1999 |
Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carmu | 2000 |